Shares of Natco Pharma Ltd were trading in the red and 1% lower on 20 June after the company received seven Form-483 observations from the US Food and Drug Administration (USFDA).

The firm reported the completion of a USFDA inspection at its pharmaceutical division in Kothur, Hyderabad, India, which took place from 9 to 19 June 2025.

Following the inspection, the company got seven observations in Form-483 and is sure that the observations will be addressed within the time frame specified, according to the company’s release.

Furthermore, the company remains committed to becoming cGMP compliant and providing high-quality products to its clients and patients worldwide.

Earlier on 13 June, the company received one observation in Form-483 from the USFDA on the completion of the inspection at the API manufacturing plant in Mekaguda, Hyderabad, India, which took place from 9 June to 13 June 2025.

On 12 September 2024 and 7 April 2025, the share reached a 52-week high of Rs 1,638.35 and a 52-week low of Rs 660.05.

At 12:06 pm, the shares of Natco Pharma were trading 0.83% lower at Rs 874.25 on NSE.

Tired of guessing stocks to trade in daily?
Unicorn Signals empowers you with powerful tools like daily stock scans for Intraday, Swing & Investing, Market Predictions and much more. Download the Unicorn Signals app today and take control of your investments!